TScan Therapeutics Inc.
TCRX | NASDAQ
$0.37
$0.00 (-0.24%)
Nov 2, 2026, 12:48 PM ET · Market open
-0.24%
(1D)No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Market Cap $22.65M
1D Range
0.35 0.40
52W Range
0.35 2.57
Valuation (TTM)
PE -0.41
PB 0.33
EV/EBITDA -0.12
Valuation (NTM)
Forward PE N/A
Forward PEG N/A
Price Target $7.50
Cash Flow
FCF Yield -522.9%
SBC Adj. FCF Yield -566.3%
SBC Impact -8.3%
Margins
Gross Margin 90.3%
Operating Margin -1695.2%
FCF Margin -1665.6%
Growth (CAGR)
Revenue 3Y | 5Y -8.6% |
56.9%
Dil EPS 3Y | 5Y 21.2% |
0.8%
FCF 3Y | 5Y -32.5% |
-364.9%
Returns
ROA -68.7%
ROE -108.7%
ROIC -75.4%
Financial Health
Net Cash
$67.38M
Current Ratio 3.37
Interest Coverage -43.22
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The compa...
Sector Healthcare
Industry Biotechnology
Employees 142
IPO Date Jul 16, 2021
Website www.tscan.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Aug 12, 2026
EPS
-$0.23
Beat +9.23%
YoY:
+17.86% REV
$1.05M
Miss -43.95%
YoY:
-65.83%Analyst Summary
# of Analysts
4
Consensus
Hold
Price Target
$1.00
Upside
+169.61%
Buy (1)
Hold (3)
Sell (0)
Add to Watchlist
Select watchlists to add or remove TCRX